SCHOTT Pharma AG & 1SXP.DE
GermanyHealthcare · Medical Instruments & SuppliesXetra · EUR
23.68 EUR (−5.8%)
13 analysts
Trading 2120.00 €Open account ↗
XTB0.00 €affiliateOpen account ↗
eToro0.86 €Open account ↗XTB0.00 €★ featured · affiliateOpen account ↗Trading 2120.00 €Open account ↗eToro0.86 €Open account ↗XTB0.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
SCHOTT Pharma AG & Co. KGaA is a German manufacturer of primary glass and polymer packaging for the pharmaceutical industry, specializing in syringes, vials, and cartridges for injectable drugs, with a business model based on selling high-precision, high-quality products to major pharmaceutical companies.
Listed on Xetra · Symbol 1SXP.DE · ETR: 1SXP · Currency EUR
Key points
from its scores- ✓Very solid balance sheet7.2
- ✕Demanding valuation3.6
- ✕Little or no dividend4.3
- ✕Weak growth4.4
AI analysis
bottom line, main risk, context and newsThe company has solid balance sheet fundamentals and revenue growth, but cash generation and earnings profitability must improve to justify the current multiple.
SCHOTT Pharma shows a healthy balance sheet (Net Debt/EBITDA of 1.14) and 10% revenue growth, but negative free cash flow conversion (-7.92) and a decline in earnings (-13.3%) weigh on its quality and valuation, which already trades at a P/E of 27.94.
The main risk is the persistent negative free cash flow conversion, which could indicate working capital management issues or unprofitable investments, eroding shareholder returns despite revenue growth.
Context and risks
SCHOTT Pharma, domiciled in Germany, operates in a strict regulatory environment for medical devices and pharmaceuticals, adding compliance and approval risk. Its primary packaging business for drugs is exposed to pricing pressure in the healthcare sector, although its niche position and structural demand for injectable drugs mitigate the impact.
Is SCHOTT Pharma AG & stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades in line with the Healthcare median (within 15%).
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 27.9 | 26.7 | +5% |
| EV / EBITDA | 16.2 | 14.5 | +12% |
| Price / book | 3.8 | 4.1 | −8% |
| Price / sales | 3.7 | 3.4 | +9% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 3.6 out of 10 (median for Healthcare: 4.7).
Average analyst target: 23.68 EUR, −5.8% versus the price.
Classic formulas with standard assumptions (10.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 27.9
- Forward P/E
- 23.0
- EV / EBITDA
- 16.2
- Price / book
- 3.8
- Price / sales
- 3.7
- Market cap
- 3.8B EUR
- Enterprise value
- 4.0B EUR
Profitability
- ROE
- 14.7%
- ROA
- 6.5%
- ROIC (approx.)
- 13.4%
- Gross margin
- 31.2%
- Operating margin
- 17.4%
- Net margin
- 13.4%
- Free cash flow
- −19.7M EUR
- FCF yield
- −0.5%
- Cash conversion
- −8%
Solvency
- Total debt
- 308.3M EUR
- Net debt
- 283.4M EUR
- Cash
- 24.9M EUR
- EBITDA
- 249.3M EUR
- Net debt / EBITDA
- 1.14
- Debt / equity
- 30.88
- Current ratio
- 1.61
- Quick ratio
- 0.74
Growth
- Revenue growth
- +10.0%
- Earnings growth
- −13.3%
- EPS (TTM)
- 0.90 EUR
- EPS (forward)
- 1.10 EUR
Dividend
- Dividend yield
- 0.7%
- Payout
- 20.0%
Risk and market
- Beta
- 0.87
- Analyst consensus
- none (13)
- Target price
- 23.68 EUR
- 52-week range
- 12.62 – 26.05
Recent news
All 1SXP.DE news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about SCHOTT Pharma AG &
Is SCHOTT Pharma AG & stock cheap or expensive?
On P/E and EV / EBITDA, it trades in line with the Healthcare median (within 15%). Valuation score: 3.6 out of 10 (median for Healthcare: 4.7). Average analyst target: 23.68 EUR, −5.8% versus the price. This is not investment advice.
What score does SCHOTT Pharma AG & get on MeridIAn Screener?
It scores 5.1 out of 10, rank 1,618 of 2,130 (better than 21% of the companies analysed). Its strongest category is Financial health (7.2) and its weakest, Valuation (3.6). Analysis of 08/10/2026.
What is SCHOTT Pharma AG &'s P/E ratio?
Its P/E is 27.9: the share price equals 27.9 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 23.0.
How much is SCHOTT Pharma AG & worth on the stock market?
Its market capitalisation is 3.8B EUR and its enterprise value, debt included, is 4.0B EUR.
How much debt does SCHOTT Pharma AG & have?
Its net debt (debt minus cash) is 283.4M EUR. That is 1.14 times its EBITDA; the Healthcare median is 1.53.
Does SCHOTT Pharma AG & pay a dividend?
Yes: its dividend yield is 0.72% and it pays out 20% of its earnings.
How has SCHOTT Pharma AG & stock performed over the last year?
It has risen 24.8% over the last year, excluding dividends. Over the last 52 weeks it has traded between 12.62 and 26.05 EUR. Past performance does not guarantee future results.
What do analysts think of SCHOTT Pharma AG &?
13 analysts cover it; their average recommendation is “none” and their average target is 23.68 EUR (−5.8% versus the price). It is an estimate, not market data.